ZindaExplore Zinda Clinic
☰
Ask ZindaHealth toolsYour guidesLibraryExploreFrameworkCasesOur methodObservatoryChai Shots

Cardiovascular · 2026 · strong signal

Compound LDLR Mutations with Attenuated FH Phenotype

Key finding

Genetic testing revealed she was homozygous for a splice-site variant and heterozygous for a frameshift variant in LDLR exon 18 — compound biallelic LDLR mutations that should, by textbook standards, produce severe homozygous FH with LDL-C often exceeding 13 mmol/L (500 mg/dL). Instead, her phenotype was attenuated. LDL-C of 5.2 mmol/L is elevated but far below what biallelic LDLR disruption typically produces. No xanthomas. No family history of premature CAD. This genotype-phenotype disconnect means standard clinical criteria for FH (Dutch Lipid Clinic Network Score, Simon Broome) would underestimate her genetic risk. She would be classified as heterozygous FH at most — missing the full severity of her underlying molecular defect. ---

Framework connections: The Fragile Engine

← All highlights · Selected public highlights are available now. Deeper material is shared only through reviewed collaborator access.

From research to a conversation

What does this mean for you?

Research can help you ask better questions. Your health history, priorities, and care decisions deserve a conversation with a clinician.

Explore Zinda Clinic
Omar Saleem, MD

Omar Saleem, MD
Founder & Clinical Director
South Asian health, in context.

Ask Zinda